Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al.).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. The impact of the covid-19 pandemic on diabetes care: the perspective of healthcare providers across Europe.Primary care diabetes · 2023
   Article
2. Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.Frontiers in pharmacology · 2022
   Review
3. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.Journal of molecular liquids · 2021
   Article

Corrections and comments

• Comment on
  Letter to the editor in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)".

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as